TrialBlood advances2023

Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.

Jia Ruan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.